IBDEI0UU ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14980,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14980,1,4,0)
 ;;=4^V12.55
 ;;^UTILITY(U,$J,358.3,14980,1,5,0)
 ;;=5^Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,14980,2)
 ;;=^340615
 ;;^UTILITY(U,$J,358.3,14981,0)
 ;;=454.9^^81^936^84
 ;;^UTILITY(U,$J,358.3,14981,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14981,1,4,0)
 ;;=4^454.9
 ;;^UTILITY(U,$J,358.3,14981,1,5,0)
 ;;=5^Varicose Veins
 ;;^UTILITY(U,$J,358.3,14981,2)
 ;;=^328758
 ;;^UTILITY(U,$J,358.3,14982,0)
 ;;=271.3^^81^937^11
 ;;^UTILITY(U,$J,358.3,14982,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14982,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,14982,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,14982,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,14983,0)
 ;;=611.1^^81^937^16
 ;;^UTILITY(U,$J,358.3,14983,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14983,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,14983,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,14983,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,14984,0)
 ;;=704.1^^81^937^17
 ;;^UTILITY(U,$J,358.3,14984,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14984,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,14984,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,14984,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,14985,0)
 ;;=251.2^^81^937^30
 ;;^UTILITY(U,$J,358.3,14985,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14985,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,14985,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,14985,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,14986,0)
 ;;=253.2^^81^937^34
 ;;^UTILITY(U,$J,358.3,14986,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14986,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,14986,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,14986,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,14987,0)
 ;;=733.00^^81^937^43
 ;;^UTILITY(U,$J,358.3,14987,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14987,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,14987,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,14987,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,14988,0)
 ;;=278.00^^81^937^40
 ;;^UTILITY(U,$J,358.3,14988,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14988,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,14988,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,14988,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,14989,0)
 ;;=278.01^^81^937^39
 ;;^UTILITY(U,$J,358.3,14989,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14989,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,14989,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,14989,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,14990,0)
 ;;=250.80^^81^937^10
 ;;^UTILITY(U,$J,358.3,14990,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14990,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,14990,1,5,0)
 ;;=5^DM Type II with LE Ulcer
 ;;^UTILITY(U,$J,358.3,14990,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,14991,0)
 ;;=250.00^^81^937^5
 ;;^UTILITY(U,$J,358.3,14991,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14991,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,14991,1,5,0)
 ;;=5^DM Type II Dm W/O Complications
 ;;^UTILITY(U,$J,358.3,14991,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,14992,0)
 ;;=250.40^^81^937^6
 ;;^UTILITY(U,$J,358.3,14992,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14992,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,14992,1,5,0)
 ;;=5^DM Type II Dm with Nephropathy
 ;;^UTILITY(U,$J,358.3,14992,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,14993,0)
 ;;=250.50^^81^937^9
 ;;^UTILITY(U,$J,358.3,14993,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14993,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,14993,1,5,0)
 ;;=5^DM Type II w/ PDR
 ;;^UTILITY(U,$J,358.3,14993,2)
 ;;=DM Type II w/ PDR^267839^362.02
 ;;
 ;;$END ROU IBDEI0UU
